Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases Imaging Download the PDF here. This post appeared first on investingnews.com
-
-
-
-
DY6 Metals Ltd (ASX: DY6, “DY6” or “Company”) is pleased to announce the initial results from the reconnaissance exploration program at the Central Rutile Project, Cameroon. Desktop studies incorporating detailed…
-
-
Investing
Alvopetro Announces May 2025 Sales Volumes and an Operational Update including 183-D4 Well Results
Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF) announces May 2025 sales volumes and an operational update, including results from our 183-D4 well. Based on cased hole logs and logs while…
-
Investing
Agreement to Acquire Major Drill-Ready Antimony-Gold-Tungsten Project in Stibnite Mining District, Idaho, USA
Resolution Minerals Ltd (“RML” or the “Company”) (ASX: RML) is pleased to announce that it has entered into a binding agreement for the acquisition of a brownfields Antimony and Gold…
-
-
CSE:NF OTCQX:NFUNF Nuclear Fuels Inc. (CSE: NF) (OTCQX: NFUNF) (‘Nuclear Fuels’ or the ‘Company ‘) announces the commencement of its 2025 drilling program, with an initial plan for at least…
-
Investing
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
Radiopharm Theranostics (ASX:RAD, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food…